NKTR

0.6259

1.65% -0.0105

Dopo l'orario di chiusura: .61 -0.0159 -2.54%

Nektar Therapeutics (NKTR)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$0.6364

Aprire:

$0.63

Volume 24 ore:

1.29M

Relative Volume:

0.56

Capitalizzazione di mercato:

$112.39M

Reddito:

$90.12M

Utile/perdita netta:

$-276.06M

Rapporto P/E:

-0.4287

EPS:

-1.46

Flusso di cassa netto:

$-193.47M

1 W Prestazione:

+3.64%

1M Prestazione:

-27.53%

6M Prestazione:

-54.97%

1 anno Prestazione:

-49.52%

Intervallo 1D:

$0.6114

$0.65

Intervallo di 1 settimana:

$0.5904

$0.6809

Portata 52W:

$0.432

$1.928

Nektar Therapeutics Stock (NKTR) Company Profile

Nome

Nektar Therapeutics

Settore

Healthcare (1182)

Industria

Biotechnology (677)

Telefono

(415) 482-5300

Indirizzo

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA

Dipendente

Cinguettio

@nektarnews

Prossima data di guadagno

2025-03-12

Ultimi documenti SEC

NKTR's Discussions on Twitter

Confronta NKTR con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
NKTR Nektar Therapeutics	0.6259	112.39M	90.12M	-276.06M	-193.47M	-1.46
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-11	Aggiornamento	Jefferies	Hold → Buy
2025-03-14	Aggiornamento	Oppenheimer	Perform → Outperform
2025-01-08	Iniziato	B. Riley Securities	Buy
2024-12-10	Iniziato	H.C. Wainwright	Buy
2024-11-04	Iniziato	Piper Sandler	Overweight
2024-09-30	Ripresa	BTIG Research	Buy
2024-06-28	Iniziato	Rodman & Renshaw	Buy
2023-11-20	Ripresa	JP Morgan	Underweight
2023-11-09	Aggiornamento	TD Cowen	Market Perform → Outperform
2023-05-10	Aggiornamento	Jefferies	Underperform → Hold
2023-02-24	Downgrade	Jefferies	Hold → Underperform
2022-08-08	Downgrade	JP Morgan	Neutral → Underweight
2022-05-31	Ripresa	Jefferies	Hold
2022-04-18	Downgrade	Goldman	Neutral → Sell
2022-03-15	Downgrade	Cowen	Outperform → Market Perform
2022-03-15	Downgrade	Mizuho	Buy → Neutral
2022-03-14	Downgrade	BTIG Research	Buy → Neutral
2022-03-14	Downgrade	BofA Securities	Neutral → Underperform
2022-03-14	Downgrade	Stifel	Buy → Hold
2022-03-14	Downgrade	William Blair	Outperform → Mkt Perform
2022-03-09	Aggiornamento	Oppenheimer	Perform → Outperform
2021-11-08	Aggiornamento	The Benchmark Company	Hold → Buy
2021-09-10	Iniziato	BofA Securities	Neutral
2021-06-28	Aggiornamento	Stifel	Hold → Buy
2021-05-18	Ripresa	Goldman	Neutral
2021-02-22	Downgrade	The Benchmark Company	Buy → Hold
2021-01-06	Iniziato	Stifel	Hold
2020-09-14	Iniziato	JP Morgan	Neutral
2020-06-10	Downgrade	CFRA	Hold → Sell
2020-05-12	Reiterato	H.C. Wainwright	Neutral
2020-04-22	Iniziato	The Benchmark Company	Buy
2020-03-30	Aggiornamento	Goldman	Sell → Neutral
2020-03-04	Iniziato	Barclays	Overweight
2020-02-03	Aggiornamento	Mizuho	Neutral → Buy
2019-10-24	Iniziato	Oppenheimer	Perform
2019-10-08	Downgrade	Goldman	Buy → Sell
2019-08-09	Downgrade	JP Morgan	Overweight → Neutral
2019-08-09	Downgrade	Jefferies	Buy → Hold
2019-08-09	Downgrade	Mizuho	Buy → Neutral
2019-03-15	Iniziato	SVB Leerink	Mkt Perform
2018-12-13	Iniziato	Goldman	Buy
2018-06-11	Downgrade	H.C. Wainwright	Buy → Neutral
2018-06-04	Reiterato	H.C. Wainwright	Buy
2018-04-20	Iniziato	Seaport Global Securities	Buy
2018-04-13	Ripresa	Piper Jaffray	Overweight
2018-04-06	Reiterato	Mizuho	Buy
2018-04-02	Ripresa	H.C. Wainwright	Buy

Mostra tutto

Nektar Therapeutics Borsa (NKTR) Ultime notizie

Apr 16, 2025

Treg Cell-Based Therapies Pipeline: 51+ Innovators Shaping the Future of Immunotherapy | DelveInsight - openPR.com

Apr 16, 2025

Jefferies Upgrades Nektar Therapeutics to Buy, Doubles Price Target to $2.00 - Yahoo Finance

Apr 11, 2025

Nektar Therapeutics Shares Rise After Upgrade From Jefferies - marketscreener.com

Apr 11, 2025

Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report? - Yahoo Finance

Apr 11, 2025

Nektar Therapeutics stock upgraded at Jefferies (NKTR:NASDAQ) - Seeking Alpha

Apr 11, 2025

Assessing Nektar Therapeutics: Insights From 5 Financial Analysts - Benzinga

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics to Buy From Hold, Adjusts Price Target to $2 From $1 - MarketScreener

Apr 11, 2025

Jefferies raises Nektar stock to buy, doubles price target By Investing.com - Investing.com India

Apr 11, 2025

Jefferies Upgrades Nektar Therapeutics (NKTR) to Buy - StreetInsider

Apr 11, 2025

Apr 10, 2025

IL-2 ADding contenders in eczema strategy - BioWorld MedTech

Apr 10, 2025

Apr 09, 2025

Nektar Therapeutics stock hits 52-week low at $0.44 By Investing.com - Investing.com Canada

Apr 09, 2025

Nektar Therapeutics stock hits 52-week low at $0.44 - Investing.com

Apr 09, 2025

Apr 04, 2025

Little Excitement Around Nektar Therapeutics' (NASDAQ:NKTR) Revenues As Shares Take 29% Pounding - simplywall.st

Apr 04, 2025

Mar 31, 2025

Q1 Dermatology Drug & Device Report: FDA Approvals & Pipeline Updates - Dermatology Times

Mar 31, 2025

Mar 29, 2025

Nektar Therapeutics announces $75 million equity distribution - Investing.com Australia

Mar 29, 2025

Mar 28, 2025

Nektar Therapeutics announces $75 million equity distribution By Investing.com - Investing.com South Africa

Mar 28, 2025

Nektar TherapeuticsEnters Equity Distribution Agreement Up To $75 MillionSEC Filing - Marketscreener.com

Mar 28, 2025